Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases

Caetano, Marcos Antônio Ferreira; Castelucci, Patrícia

doi:10.12998/wjcc.v10.i28.9985

Cited by 28 publications

(17 citation statements)

References 222 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 69 It is possible that utilization of ROS by Enterobacteriaceae , along with increased abundance of short-chain fatty acid producing bacteria, such as Lactobacillaceae and Enterococcaceae , may have played a role in minimizing intestinal damage caused by the oxidative environment in LM pups. 70 , 71 , 72 Furthermore, despite normalization of Nox1 expression upon feeding of CON diet, the abundance of intestinal Enterobacteriaceae remained high. Our findings align with the ‘window of opportunity’ and developmental origins of health and disease hypotheses, indicating that the gut microbiota composition is particularly responsive to early-life environmental factors like diet, with reduced plasticity in the microbiome thereafter.…”

Section: Discussionmentioning

confidence: 99%

A Murine Model of Maternal Micronutrient Deficiencies and Gut Inflammatory Host-microbe Interactions in the Offspring

Holani,

Littlejohn,

Edwards

et al. 2024

Cellular and Molecular Gastroenterology and Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A Murine Model of Maternal Micronutrient Deficiencies and Gut Inflammatory Host-microbe Interactions in the Offspring

Holani,

Littlejohn,

Edwards

et al. 2024

Cellular and Molecular Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…Three groups of patients (early-stage CDK of unknown etiology [CKDu]; early-stage CKD with underlying diseases [CKD-UD]; and patients with underlying diseases, but not CKD [UD]) and one group of healthy controls (HC) were enrolled in this study. The results obtained herein will provide a more detailed understanding of the gut microbiota and SCFA concentrations in early-stage CKD, which may lead to better approaches for the diagnosis of early-stage CKD and therapeutic strategies to prevent its progression ( Feng et al , 2018 ; Alsharairi, 2022 ; Caetano and Castelucci, 2022 ).…”

mentioning

confidence: 91%

Slight Changes in the Gut Microbiome in Early-stage Chronic Kidney Disease of Unknown Etiology

Banjong,

Pongking,

Tran

et al. 2023

Microb. Environ.

View full text Add to dashboard Cite

Gut dysbiosis and changes in short-chain fatty acids (SCFAs) occur in end-stage chronic kidney disease (CKD); however, the degree of these changes in the gut microbiome and serum SCFA profiles in the early stages of CKD,‍ ‍particularly in‍ ‍CKD‍ ‍of unknown etiology (CKDu), is unclear. We herein investigated the gut microbiome and SCFA profiles of early-stage CKD patients (CKD stages 1–3) in a community in Khon Kaen Province, Thailand. Seventy-two parasite-free participants were distributed among a healthy control group (HC, n =18) and three patient groups (an underlying disease group [UD, n =18], early-stage CKD with underlying disease [CKD-UD, n =18], and early-stage CKD of unknown etiology, [CKDu, n =18]). Fecal DNA was individually extracted and pooled for groups of six individuals (three pools in each group) to examine the composition of the gut microbiome using next-generation sequencing. A SCFA analysis was performed on serum samples from each individual using gas chromatography-mass spectrometry. The results revealed that microbial abundance differed between the healthy group and all patient groups (UD, CKD-UD, and CKDu). [Eubacterium]_coprostanoligenes_ group was more abundant in the CKDu group than in the HC and CKD-UD groups. Furthermore, serum concentrations of acetate, a major SCFA component, were significantly lower in all patient groups than in the HC group. The present results indicate that minor changes in the gut microbiome and a significant decrease in serum acetate concentrations occur in early-stage CKDu, which may be important for the development of prevention strategies for CKD patients.

show abstract

“…Short chain fatty acids (SCFA) such as acetate, propionate, butyrate, and isobutyrate are derived from microbial fermentation of dietary fibers, and their fecal levels have been assessed in patients with IBD [ 14 ]. At this time, data are not consistent and there are reports of reduced as well as unchanged fecal SCFA levels of patients with IBD in comparison to healthy controls [ 15 – 19 ].…”

Section: Introductionmentioning

confidence: 99%

Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity

Tews,

Elger,

Gunawan

et al. 2023

Lipids Health Dis

View full text Add to dashboard Cite

Background Urinary 3-indoxyl sulfate levels as well as fecal short chain fatty acid (SCFA) concentrations are surrogate markers for gut microbiota diversity. Patients with inflammatory bowel diseases (IBDs) and patients with primary sclerosing cholangitis (PSC), a disease closely associated with IBD, have decreased microbiome diversity. In this paper, the fecal SCFAs propionate, acetate, butyrate and isobutyrate of patients with IBD and patients with PSC-IBD and urinary 3-indoxyl sulfate of IBD patients were determined to study associations with disease etiology and severity. Methods SCFA levels in feces of 64 IBD patients and 20 PSC-IBD patients were quantified by liquid chromatography with tandem mass spectrometry (LC–MS/MS). Urinary 3-indoxyl sulfate levels of 45 of these IBD patients were analysed by means of reversed-phase liquid chromatography-electrospray ionization-tandem mass spectrometry. Feces of 17 healthy controls and urine of 13 of these controls were analyzed in parallel. These cohorts had comparable sex distribution and age. Results Urinary 3-indoxyl sulfate concentrations (normalized to urinary creatinine levels) was increased (P = 0.030) and fecal isobutyrate levels (normalized to dry weight of the stool sample) of IBD patients were decreased (P = 0.035) in comparison to healthy controls. None of the analyzed metabolites differed between patients with Crohn´s disease (CD) and patients with ulcerative colitis (UC). Fecal acetate and butyrate positively correlated with fecal calprotectin (P = 0.040 and P = 0.005, respectively) and serum C-reactive protein (P = 0.024 and P = 0.025, respectively) in UC but not CD patients. UC patients with fecal calprotectin levels above 150 µg/g, indicating intestinal inflammatory activity, had higher fecal acetate (P = 0.016), butyrate (P = 0.007) and propionate (P = 0.046) in comparison to patients with fecal calprotectin levels < 50 µg/g. Fecal SCFA levels of PSC-IBD and IBD patients were comparable. Conclusions Current findings suggest that analysis of urinary 3-indoxyl-sulfate as well as fecal SCFAs has no diagnostic value for IBD and PSC-IBD diagnosis or monitoring of disease severity.

show abstract

Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases

Cited by 28 publications

References 222 publications

A Murine Model of Maternal Micronutrient Deficiencies and Gut Inflammatory Host-microbe Interactions in the Offspring

A Murine Model of Maternal Micronutrient Deficiencies and Gut Inflammatory Host-microbe Interactions in the Offspring

Slight Changes in the Gut Microbiome in Early-stage Chronic Kidney Disease of Unknown Etiology

Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity

Contact Info

Product

Resources

About